Simultaneous determination of pioglitazone and glimepiride in bulk drug and pharmaceutical dosage from by RP-HPLC METHOD

A simple, fast, and precise reverse phase, isocratic HPLC method was developed for the separation and quantification of pioglitazone and glimepiride in bulk drug and pharmaceutical dosage form. The quantification was carried out using Inertsil ODS [250 x 4.6 mm, 5micro] column and mobile phase comprised of acetonitrile and ammonium acetate [pH 4.5; 20mM] in proportion of 60:40 [v/v]. The flow rate was 1.0 ml/min and the effluent was monitored at 230 nm. The retention time of pioglitazone and glimepiride were 7.0 +/- 0.1 and 10.2 +/- 0.1 min respectively. The method was validated in terms of linearity, precision, accuracy, and specificity, limit of detection and limit of quantitation. Linearity of pioglitazone and glimepiride were in the range of 2.0 to 200.0microg/ml and 0.5-50microg/ml respectively. The percentage recoveries of both the drugs were 99.85% and 102.06% for pioglitazone and glimepiride respectively from the tablet formulation. The proposed method is suitable for simultaneous determination of pioglitazone and glimepiride in pharmaceutical dosage form and bulk drug

Biodegradable implants of gentamicin sulfate for effective management of osteomyelitis

The purpose of the present study was to prepare and evaluate rod shaped biodegradable implants of gentamicin sulfate using poly[epsilon-caprolactone] [PCL]. The implants were prepared by melt extrusion method with different ratios of drug and PCL [1:1, 1:1.5 and 1:2] and evaluated for drug content, in vitro drug release, stability studies and in vivo evaluation in healthy rabbits. The implants were found to be uniform with respect to weight, diameter, length and drug content. In the in vitro drug release studies, implants released the drug in a biphasic pattern with an initial burst release followed by a slow release over a period of 80 days. In the in vivo experiment, the gentamicin concentration of bone was maintained above the minimum inhibitory concentration for Staphylococcus aureus over a period of 4 weeks. In the stability studies, the implants exhibited no change in the drug content after 6 months at refrigeration temperature and 25°C. The present study reveals the applicability of biodegradable gentamicin implants to treat bone disorders